<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807755</url>
  </required_header>
  <id_info>
    <org_study_id>UCDCC#214</org_study_id>
    <secondary_id>200816670</secondary_id>
    <secondary_id>CRAD001CUS41T</secondary_id>
    <secondary_id>UCDCC-214</secondary_id>
    <nct_id>NCT00807755</nct_id>
  </id_info>
  <brief_title>Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as carboplatin and etoposide, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving more than one drug&#xD;
      (combination chemotherapy) together with everolimus may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of everolimus,&#xD;
      carboplatin, and etoposide in treating patients with small cell lung cancer or other advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of everolimus combined with carboplatin and&#xD;
           etoposide in patients with advanced solid tumors, with emphasis on small cell lung&#xD;
           cancer (SCLC).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the maximum-tolerated dose of this regimen in these patients.&#xD;
&#xD;
        -  Describe the dose-limiting toxicities and toxicity profile associated with this regimen&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen in an expanded cohort of patients&#xD;
           with SCLC.&#xD;
&#xD;
        -  Assess the pharmacokinetic parameters of everolimus in this combination.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral everolimus on days 1-21, carboplatin IV over 15-30 minutes on day 1,&#xD;
      and etoposide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients in the expanded cohort undergo blood collection on days 1, 15, and 22 for&#xD;
      pharmacokinetic studies by liquid chromatography-tandem mass spectrometry.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Number of known toxicities observed despite a treatment-naïve population&#xD;
  </why_stopped>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and feasibility of combining RAD001 with carboplatin and etoposide in advanced solid tumors, with emphasis on SCLC.</measure>
    <time_frame>Up to 1 year from start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum-tolerated dose as assessed by NCI CTCAE, Version 3.0</measure>
    <time_frame>April 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicities and toxicity profile as assessed by NCI CTCAE, Version 3.0</measure>
    <time_frame>Up to one year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of this regimen in patients with small cell lung cancer</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory biomarker analysis</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Phase I Dose-Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.</description>
    <arm_group_label>Phase I Dose-Escalation</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.</description>
    <arm_group_label>Phase I Dose-Escalation</arm_group_label>
    <other_name>Eposin</other_name>
    <other_name>Etopophos</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).</description>
    <arm_group_label>Phase I Dose-Escalation</arm_group_label>
    <other_name>Everolimus</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumors for which curative&#xD;
             standard treatments are not available&#xD;
&#xD;
               -  Ten additional patients with extensive stage small cell lung cancer are accrued&#xD;
                  to the expanded cohort once a maximum tolerate dose (or a dose for further&#xD;
                  exploration) is determined&#xD;
&#xD;
                    -  Must be chemotherapy naive&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Prior irradiated disease sites are considered measurable if there is clear&#xD;
                  disease progression following radiation therapy&#xD;
&#xD;
          -  No uncontrolled brain or leptomeningeal metastases (including those requiring&#xD;
             glucocorticoids)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 1.3 mg/dL OR creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 mg/dL (regardless of liver involvement)&#xD;
&#xD;
          -  SGOT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  INR ≤ 1.3 (≤ 3 if on anticoagulation)&#xD;
&#xD;
          -  Fasting serum cholesterol ≤ 300 mg/dL*&#xD;
&#xD;
          -  Fasting triglycerides ≤ 2.5 times ULN*&#xD;
&#xD;
          -  No severe and/or uncontrolled medical co-morbidities or other conditions that could&#xD;
             affect participation in the study including, but not limited to, the following:&#xD;
&#xD;
               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction ≤ 6 months prior to first study treatment&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Severely impaired lung function&#xD;
&#xD;
               -  Active (acute or chronic) or uncontrolled infection&#xD;
&#xD;
               -  Non-malignant medical illness that is uncontrolled or that the control may be&#xD;
                  jeopardized by the study therapy&#xD;
&#xD;
               -  Liver disease (i.e., cirrhosis, chronic active hepatitis, chronic persistent&#xD;
                  hepatitis)&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (i.e., fasting serum glucose &gt; 1.5 times ULN)&#xD;
&#xD;
          -  No HIV seropositivity&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
               -  No oral, implantable, or injectable contraceptives&#xD;
&#xD;
          -  No impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of everolimus (e.g., ulcerative disease,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel&#xD;
             resection)&#xD;
&#xD;
          -  No active, bleeding diathesis&#xD;
&#xD;
          -  No known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus,&#xD;
             temsirolimus) or to its excipients&#xD;
&#xD;
          -  Must be able to take and retain oral medication&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1 as per NCI CTCAE vs. 3 NOTE: *In case one or both&#xD;
             of these thresholds are exceeded, the patient can only be included after initiation of&#xD;
             appropriate lipid-lowering medication.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 3 weeks since prior and no concurrent investigational drugs&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery or completion of radiotherapy&#xD;
&#xD;
          -  No immunization with attenuated live vaccines within the past week or during study&#xD;
             therapy&#xD;
&#xD;
          -  No prior treatment with an mTOR inhibitor (e.g., sirolimus, temsirolimus, or&#xD;
             everolimus)&#xD;
&#xD;
          -  No chronic treatment with systemic steroids or other immunosuppressive agents&#xD;
&#xD;
          -  No concurrent oral anti-vitamin K medication (except low dose coumadin)&#xD;
&#xD;
          -  No concurrent medications interfering with everolimus&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gandara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California School of Medicine - Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2008</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

